Esreboxetine
Esreboxetine is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued. It is the --enantiomer of reboxetine and is even more selective in comparison.
However, recently it has been shown that esreboxetine could be effective in fibromyalgia patients.
